Kala Bio Secures Exclusive U.S. Rights to Virotek’s Ophthalmology Genetic Testing Program

Key Points

• Kala Bio finalized an exclusive U.S. distribution and reseller agreement with Virotek for its ophthalmology genetic testing and screening program.
• The agreement begins September 4, 2026, and provides Kala with one year of U.S. exclusivity, subject to commercial milestone requirements.
• Virotek will continue to operate testing infrastructure, supply collection kits, process specimens, and produce clinical reports.
• The companies agreed to a profit-sharing structure that becomes effective after Virotek recovers program costs.
• The deal also gives Kala a right of first refusal on certain future Virotek ophthalmology products and services.

Kala Bio (Nasdaq: KALA) has finalized a definitive agreement with Virotek that gives Kala exclusive rights to market, promote, distribute, and resell Virotek’s ophthalmology genomic testing program across the United States.

The agreement follows a non-binding letter of intent announced September 1 and takes effect September 4. Kala’s exclusive distribution rights initially run for one year. The company must meet agreed commercial milestones to retain exclusivity beyond that period.

Kala Takes U.S. Commercial Role for Genetic Testing Program

Under the agreement, Kala will lead the U.S. commercial effort for Virotek’s ophthalmology genetic testing and screening program.

Virotek will continue to manage the program’s operational and clinical functions. Those responsibilities include maintaining testing infrastructure, supplying kits, processing patient specimens, and delivering clinical reports.

Virotek will also provide training and program materials to Kala’s distribution partners. The arrangement allows Kala to focus on sales, marketing, channel development, and customer access without taking responsibility for laboratory operations.

Profit Sharing Begins After Virotek Recovers Costs

The companies agreed to a profit-sharing structure for the genetic testing program. Profit sharing will begin after Virotek recovers its program costs.

The announcement did not disclose the commercial milestones Kala must meet, the length of any extended exclusivity period, revenue-sharing percentages, cost-recovery terms, minimum sales commitments, upfront payments, or projected revenue.

As a result, investors cannot yet determine the near-term financial impact of the agreement.

Agreement Creates Potential Expansion Into Oncology and Preventive Health

The partnership includes a right of first refusal for Kala on certain Virotek ophthalmology products and services that Virotek may later seek to sell or license to another party.

The companies also created a framework to expand the relationship into additional clinical areas by mutual agreement. Potential areas include oncology, preventive-health testing, telehealth, and white-label distribution.

These opportunities remain potential future initiatives. The announcement does not establish that Kala or Virotek has launched, funded, or committed to commercialize these additional programs.

Ophthalmology Program Targets Inherited Retinal Disease Testing

Kala said the agreement addresses demand for genetic testing among patients with inherited retinal diseases.

According to third-party market research cited by the companies, the U.S. genetic testing market was valued at about $5.7 billion in 2025 and is projected to reach about $6.9 billion in 2026.

Peer-reviewed prevalence studies cited in the release estimate inherited retinal diseases affect about one in every 3,450 people. U.S. registry data recorded more than 40,000 new diagnoses of retinitis pigmentosa, choroideremia, and achromatopsia during a seven-year period.

Kala believes Virotek’s program can address this population through non-invasive specialist-administered collection and broad multi-gene panel coverage. These views reflect the company’s assessment, and the release does not provide revenue projections or adoption data for the program.

Kala Uses Staged Partnership Model to Build Scale

Kala said the Virotek agreement fits its strategy of building operating scale through staged, capital-efficient partnerships, growth initiatives, and acquisitions.

The company believes the approach enables it to deploy capital selectively, manage execution risk, and maintain flexibility while it assesses other opportunities.

Kala and Virotek may also explore adding U.S.-based laboratory capacity in the future. Any expansion would require further agreement on scope, costs, and timing.

The agreement gives Kala a new commercial opportunity in ophthalmology genetic testing, but its value will depend on execution, commercial milestone achievement, customer adoption, reimbursement, partner performance, and the undisclosed financial terms of the profit-sharing arrangement.